AMBIGUOUS RESULTS

Cyllene reports sustained incontinence drop with EG110A gene therapy in 16-patient trial

The Phase 1/2 readout in spinal-cord-injury patients reports durable incontinence reductions at 9 months, but Cyllene disclosed no incidence numbers, p-values, or comparator data.

By AppliedXLJuly 7, 2026Trial NCT06596291

Executive Summary

Cyllene Therapeutics disclosed that its gene therapy candidate produced a sustained drop in incontinence episodes months after a single treatment, in patients who had run out of standard options.
The company did not report the actual incidence numbers, a statistical comparison, or how many of the enrolled patients the durability claim covers, leaving the size of the effect unverifiable from the disclosure alone.
The trial is designed to test safety first, and the company is already signaling a move toward a larger, later-stage study, so the readout functions as a bridge to that decision rather than a controlled efficacy result.
The therapy sits alone in its own mechanism corner of the bladder-control field, with no direct comparator by target found in the current landscape, which raises both the scientific stakes of the mechanism and the burden of proof on any efficacy claim.

The disclosure

Cyllene Therapeutics, formerly EG 427, disclosed the result inside a July 7, 2026 press release announcing a €33 million Series C financing and a corporate rebrand. The company said EG110A "continues to demonstrate efficacy and safety results" in patients with neurogenic detrusor overactivity after spinal cord injury, with sustained reductions in urinary incontinence episodes 9 months post treatment. No incidence figures, confidence intervals, or statistical tests accompanied the claim, and the trial's ClinicalTrials.gov record does not yet carry posted results. Cyllene

Probability of Success

Endpoint Met11%

Completes65%

Clinical Significance9%

Regulatory16%

The trial design

The study, NCT06596291, is a Phase 1/2, non-randomized, open-label dose-escalation trial delivering EG110A by intradetrusor injection (directly into the bladder muscle) to adults with spinal cord injury who perform clean intermittent catheterization. Its registered primary endpoint is the incidence of treatment-emergent adverse events, with bladder-diary incontinence episodes and urodynamic measures at weeks 12 and 52 as secondary endpoints. The trial targets 16 patients across three experimental arms, has enrolled to that target, and lists Recruiting status with a primary completion date of June 1, 2027. NCT06596291

Safety and maturity

The company characterizes the safety profile as favorable, consistent with a trial whose primary endpoint is tolerability rather than efficacy. The efficacy claim, however, is drawn from a small, open-label cohort without a comparator arm, and the disclosure did not specify how many of the 16 enrolled patients the 9-month durability figure covers. The primary completion date has moved twice, from March 2027 to April 2027 in mid-2025 and then to June 2027 in February 2026, a cumulative 92-day slip that the trial's own operational tracking flags as a moderate-severity signal alongside two rounds of eligibility-criteria changes. Cyllene+1

Competitive and mechanistic context

EG110A is a non-replicating HSV-1 vector designed to selectively target type C sensory neurons, the sensory nerve fibers implicated in bladder overactivity, delivered locally into the detrusor muscle. No competitor sharing that target was identified in the current landscape scan, and the nearest indication-level comparators, an oral beta-3 agonist in pediatric NDO and a urologic scaffold for stress incontinence, work through unrelated mechanisms and do not bear on this readout. That isolation means the mechanism has no resolved precedent to benchmark durability or safety against within this population, so the trial's own longer-term follow-up, including the observational study planned out to 5 years, becomes the only available evidence base for the therapy's mechanism. Cyllene

What comes next

Cyllene said it plans to start a Phase 2b/3 study of EG110A in 2027 to further evaluate dosing, safety, efficacy, and durability, alongside a separate observational study following patients for up to 5 years. The company is also expanding into additional indications, including overactive bladder. Those plans indicate the sponsor is treating the current 9-month signal as sufficient to justify capital deployment toward a larger trial, even though the underlying dose-escalation study has not completed and has not posted registry-level results. Cyllene

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.